Marginal Zone Lymphoma
📧 Sign up to get email alerts when something new happens for Marginal Zone Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-11-14Clinical Trial Update: A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating CTX112 in relapsed or refractory B-cell malignancies is currently recruiting.
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma [Phase 1]
This document provides an update on a Phase 1 clinical trial evaluating the combination of lenalidomide and ibrutinib in patients with relap…
-
CLINICAL_TRIALS research · 2025-11-06Clinical Trial Update: Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) [Phase 1]
Phase 1 clinical trial evaluating the combination of Rituximab and Tafasitamab with allogeneic NK cells in relapsed/refractory B-cell non-Ho…
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma [Phase 1]
This update outlines a Phase 1 study of genetically modified T-cell infusions following peripheral blood stem cell transplant for patients w…
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL [Phase 2]
A Phase 2 clinical trial update evaluating orelabrutinib combined with zebetuzumab and lenalidomide for newly diagnosed marginal zone lympho…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-09-30Clinical Trial Update: Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma [Phase 2]
Open-label Phase 2 trial evaluating loncastuximab tesirine (ADCT-402) in relapsed/refractory marginal zone lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical trial update describes an ongoing Phase 1/2 study of selinexor in combination chemotherapy for advanced B-cell non-Hodgkin lymphoma…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 clinical trial update evaluating the combination of nivolumab and lenalidomide in relapsed or refractory lymphomas (non-Hodgkin an…
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
This clinical trial update reports that recruitment is ongoing for a study evaluating zanubrutinib in patients with Waldenström's macroglobu…
-
CLINICAL_TRIALS research · 2025-09-15Clinical Trial Update: Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma [Phase 3]
A Phase 3 clinical trial comparing orelabrutinib plus rituximab versus lenalidomide plus rituximab in relapsed/refractory marginal zone lymp…
-
CLINICAL_TRIALS research · 2025-09-15Clinical Trial Update: An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment [Phase 1]
Early-phase trial evaluating a three-drug combination (venetoclax, lenalidomide, and rituximab with hyaluronidase) in relapsed or refractory…
-
CLINICAL_TRIALS research · 2025-09-11Clinical Trial Update: CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas [Phase 1]
This entry provides an update on an ongoing Phase 1 trial of CD19-targeted CAR T-cells (CD19.20.22) for relapsed/refractory B-cell lymphomas…
-
CLINICAL_TRIALS research · 2025-09-09Clinical Trial Update: Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 clinical trial update evaluating the combination of obinutuzumab, venetoclax, and lenalidomide in patients with relapsed or refrac…
-
CLINICAL_TRIALS research · 2025-08-12Clinical Trial Update: HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL [Phase 2]
This is an update on a Phase 2 clinical trial evaluating tafasitamab in combination with lenalidomide and rituximab in treatment-naive folli…
-
CLINICAL_TRIALS research · 2025-08-07Clinical Trial Update: AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas [Phase 1]
Phase 1 clinical trial evaluating autologous CD22-directed CAR-T cells in patients with recurrent or refractory B-cell lymphomas, including …
-
CLINICAL_TRIALS research · 2025-07-31Clinical Trial Update: 64Cu-LLP2A for Imaging Hematologic Malignancies [EARLY_Phase 1]
Phase 1 imaging trial evaluating 64Cu-LLP2A in hematologic malignancies is currently recruiting, targeting multiple myeloma and various lymp…
-
CLINICAL_TRIALS research · 2025-07-23Clinical Trial Update: A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma [Phase 3]
A Phase 3 clinical trial studying the combination of ibrutinib and rituximab in untreated marginal zone lymphoma is currently active and not…
-
CLINICAL_TRIALS research · 2025-06-27Clinical Trial Update: Combating Cancer-Related Fatigue: A Personalized Supportive Care Program [NA]
This clinical trial update reports a UNC Lineberger Comprehensive Cancer Center study recruiting participants for a personalized supportive …
-
CLINICAL_TRIALS research · 2025-06-17Clinical Trial Update: Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial [Phase 2]
A randomized Phase II trial evaluating orelabrutinib plus rituximab versus R-CVP in untreated marginal zone lymphoma (MZL). The study is cur…
-
CLINICAL_TRIALS research · 2025-06-06Clinical Trial Update: BR Combined With OR in Treatment-naïve Marginal Zone Lymphoma [Phase 2]
Clinical trial update for a Phase 2 study evaluating BR combined with OR in treatment-naïve marginal zone lymphoma; recruitment status is NO…
-
CLINICAL_TRIALS research · 2025-05-22Clinical Trial Update: Orelabrutinib Combined With Zuberitamab in the Initial Treatment of MZL [Phase 2]
A Phase 2 trial is exploring orelabrutinib combined with zuberitamab as initial therapy for marginal zone lymphoma and is currently recruiti…
-
CLINICAL_TRIALS research · 2025-04-04Clinical Trial Update: Copanlisib and Rituximab in Marginal Zone Lymphoma Patients [Phase 2]
Phase 2 trial update indicates a study of copanlisib in combination with rituximab for marginal zone lymphoma is currently active but not re…
-
CLINICAL_TRIALS research · 2025-02-24Clinical Trial Update: A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies [Phase 1]
Phase 1 clinical trial update for BP1002 in advanced lymphoid malignancies across several B-cell and T-cell lymphomas; trial status is activ…
-
CLINICAL_TRIALS research · 2025-02-12Clinical Trial Update: Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)
This clinical trial update describes a study to evaluate the effectiveness and safety of zanubrutinib in Italian patients with marginal zone…
-
CLINICAL_TRIALS research · 2025-02-04Clinical Trial Update: Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas
A clinical trial in Italy is evaluating clinical characteristics and outcomes in patients with Marginal Zone Lymphoma. The study is currentl…